Compare Futu Holdings Ltd (FUTU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Novo Nordisk A/S — how do they compare? Futu Holdings Ltd trades at $105.95 (market cap $14.74B), while Novo Nordisk A/S trades at $45.88 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 14.1× Futu Holdings Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| FUTU | NVO | |
|---|---|---|
Market Cap | $14.74B | $207.85B |
Sector | Financials | Health |
52-Week High | $199.04 | $63.98 |
52-Week Low | $89.76 | $35.29 |
Enterprise Value | $14.59B | $222.55B |
Dividend Yield | 2.47% | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
